Growth hormone is divided into two dosage forms, one is short-acting and the other is long-acting. Short-acting growth hormone needs to be injected once a day before going to bed, while long-acting growth hormone only needs to be injected once a week. As an upgraded product, the research and development of long-acting growth hormone has become a global hot spot. Fortunately, the domestic long-acting growth hormone research and development technology has long been at the forefront of the world. In 2014, domestically produced long-acting growth hormone was launched, which was also the world’s first long-acting growth hormone drug. Because of its huge technological innovation in the research and development of long-acting growth hormone, it won the National Science and Technology Progress Award in 2015. Professor Cohen, the former chairman of the International Growth Hormone Association, commented that Jinsaizeng is the greatest progress made since growth hormone was launched on the market.
1. Zero detection of antibodies, safer and more secure to use
Antibodies in biological preparations are very harmful. If antibodies are generated during the use of drugs and immune complexes are formed in the body, not only It will reduce the efficacy of the medicine, and immune complexes may also be deposited in organs with slow blood flow, such as kidneys, joints, etc., posing long-term safety risks and hazards. Therefore, the FDA has zero tolerance for antibodies from biological agents. Long-acting growth hormone effectively maintains the natural structure of growth hormone through unique PEG coupling technology, which can reduce or eliminate the immunogenicity of the drug. A clinical study of more than 2,000 cases in Phase IV clinical trials showed that the antibody detection rate was zero. Zero antibodies, safer and more secure for children to use.
2. Phase IV clinical verification with the largest sample size in the world, safety guaranteed
Compared with short-acting growth hormone, long-acting growth hormone prepared by unique PEG coupling technology, It well simulates the biological effects of human growth hormone in the body. The drug continues to exert its efficacy in the body, and the blood drug concentration is maintained within a stable and safe range without accumulation. Since 2014, it has been used in more than 10,000 Asian children, with the longest medication time being up to 4 years. After long-term monitoring of patients taking the medication, it is safe and effective. In the 3-year phase IV clinical trial, it passed the actual test of 3,000 drug-taking patients, the largest sample size in the world, and found that it is safe for long-term use.
Safe, effective, and convenient, it optimizes the treatment experience of children’s growth hormone. It is believed that the treatment of short children will definitely enter the long-term era in the future.